DexCom, Inc. $DXCM Stock Position Decreased by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 43.4% during the third quarter, Holdings Channel reports. The firm owned 22,984 shares of the medical device company’s stock after selling 17,591 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $1,547,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Intact Investment Management Inc. raised its holdings in DexCom by 102.9% during the 3rd quarter. Intact Investment Management Inc. now owns 33,890 shares of the medical device company’s stock worth $2,280,000 after buying an additional 17,190 shares during the period. MBM Wealth Consultants LLC boosted its holdings in shares of DexCom by 4.1% in the third quarter. MBM Wealth Consultants LLC now owns 9,228 shares of the medical device company’s stock worth $621,000 after buying an additional 361 shares during the period. Sector Gamma AS increased its position in shares of DexCom by 53.6% in the third quarter. Sector Gamma AS now owns 76,821 shares of the medical device company’s stock worth $5,169,000 after acquiring an additional 26,821 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of DexCom by 29.8% in the third quarter. CIBC Asset Management Inc now owns 156,185 shares of the medical device company’s stock worth $10,510,000 after acquiring an additional 35,824 shares in the last quarter. Finally, GDS Wealth Management raised its holdings in shares of DexCom by 5.9% during the third quarter. GDS Wealth Management now owns 200,452 shares of the medical device company’s stock valued at $13,488,000 after acquiring an additional 11,134 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent analyst reports. Mizuho raised their price objective on shares of DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Royal Bank Of Canada decreased their target price on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Truist Financial reiterated a “buy” rating and set a $82.00 price target (down previously from $94.00) on shares of DexCom in a report on Monday, November 3rd. Canaccord Genuity Group set a $99.00 price target on DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.30.

DexCom Trading Down 0.4%

NASDAQ DXCM opened at $73.36 on Thursday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $28.61 billion, a PE ratio of 40.76, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. The firm’s fifty day simple moving average is $67.25 and its 200-day simple moving average is $70.92.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the firm earned $0.45 earnings per share. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the sale, the director directly owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach purchased 18,200 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This represents a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 7,866 shares of company stock valued at $448,177 in the last three months. Corporate insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.